Subgroup analysis by type of chemotherapy showed that median PFS was significantly higher with crizotinib than with either pemetrexed HR: Related articles in Web of Science Google Scholar. Several ALK inhibitors have been introduced in clinical trials or are currently under preclinical development. Patients should also be educated about signs and symptoms of drug-induced liver injury and hepatic failure [ 34 ]. Although grade 1 AEs including visual disturbance and nausea were noted 3 days after administration of crizotinib, a partial response was achieved at 4 weeks. Additionally, HGF is reportedly produced by bone marrow stromal cells and plays a role in promoting hematopoiesis via the c-Met receptor [ 9 ].
Patients received crizotinib mg twice daily in day cycles until progression or intolerable adverse events. Gastrointestinal endoscopic examination 10 days after the initiation of crizotinib treatment revealed multiple erosive lesions with a white coating in the middle thoracic portion of the esophagus. Several ALK inhibitors have been introduced in clinical trials or are currently under preclinical development. It is possible that the efficacy of pemetrexed in the present case was associated with ALK positivity. Gastrointestinal adverse events were common in crizotinib studies but were generally mild or moderate and could usually be managed with supportive care rather than dose reduction or interruption [ 34 ].
Limited clinical experience and information concerning the management of AEs associated with both crizotinib and alectinib treatment is currently available. Xaklori, crizotinib therapy was initiated.
XALKORI case study | TIGCRU Insight
There was no significant difference in overall survival between treatment groups HR for death with crizotinib: The discovery of hepatocyte growth factor HGF and its significance for cell biology, life sciences and clinical medicine. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer — clinical results and biomarker analysis of GeparNuevo study.
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer AFJG: For example, one study of platinum-based chemotherapy regimens for advanced NSCLC patients resulted in a median survival of 7.
Although the clinical significance and long-term effects of bradycardia and QTc prolongation in patients receiving crizotinib are unclear, caution should be taken for patients with a history of or predisposition for QTc prolongation [ 34 ]. Firstly, ALK positivity is associated with lower levels of thymidylate synthase, one of the targets of pemetrexed In this case, the patient exhibited an eminently prolonged response to pemetrexed, dalkori preceded crizotinib treatment.
Furthermore, at the time of writing, in post-marketing surveillance in Japan 8three cases of esophageal ulcers and six of esophagitis caused by crizotinib were reported; among these nine cases, three were severe. A previous study proved that HGF stimulates epithelial cell proliferation, motility, morphogenesis, and angiogenesis via tyrosine phosphorylation of its receptor, c-Met, and plays a role in self-repair of various injured organs [ 8 ].
Non-small-cell lung cancer NSCLC is associated with a poor prognosis and low survival rates, providing a strong rationale for the development of new treatment options.
Eight days later, the patient was unable to eat or drink. This article has been cited by other articles in PMC. Nakamura T, Mizuno S. Xalkoti, grade 4 neutropenia neutrophil count: These patients were enrolled into an expanded cohort of an ongoing phase I study PROFILE and received crizotinib mg twice daily in day cycles, a dose which was established in the dose-escalation phase of the study.
Directors of Clinical Research programs: Estimated median PFS was 8.
XALKORI case study
This is illustrated by a recent report of sequential ALK inhibitor therapy that demonstrates the utility of re-biopsy in providing patients with a personalised treatment sequence [ 45 ]. Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer. Introduction Crizotinib is the first clinically available inhibitor of anaplastic lymphoma kinase ALK gene rearrangement and has shown notable antitumor effects in patients with ALK-positive non-small cell lung cancer NSCLC [ 123 ].
Treating ALK-positive lung cancer – early successes and future challenges.
Gastrointestinal endoscopic stjdy 10 days after the initiation of crizotinib revealed severe esophagitis in the middle thoracic portion Fig. There was no recurrence of the esophageal symptoms. As well as improving QoL scores, crizotinib also significantly improved pain, dyspnoea and insomnia QLQ-C30 ; and dyspnoea, cough, chest pain, arm or shoulder pain and pain in other parts QLQ-LC13 [ 27 ].
Here we present the case of a year-old patient who presented with multiple pulmonary nodules, a left pleural effusion and an ovarian tumor.
Subsequently, crizotinib was re-administered at the initial dose.
Sign In or Create an Account. It furthers the University’s objective of excellence in research, scholarship, and education by publishing worldwide.
Esophagitis has not been reported as a major crizotinib-related adverse event in previous studies, although three cases of esophagitis two cases of grade 1 and one of grade 2 were reported among patients in phase I and II trials 7. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.
Active EGFR mutations were not identified.